Bayer considering sale of its diabetes device business

London

BAYER AG is exploring the sale of its diabetes device business as the German company focuses on faster-growing medicines, according to people with knowledge of the matter.

Leverkusen, Germany-based Bayer is working with Credit Suisse Group AG on the potential sale, three of the people said, asking not to be identified because the process is private.